analysis from most: disease progression and leukemic transformation in lower-risk myelofibrosis
Published 1 year ago • 119 plays • Length 3:35Download video MP4
Download video MP3
Similar videos
-
3:23
molecular characteristics associated with increased risk of disease progression in smm
-
2:08
real-world analysis of the most study: factors impacting progression to mf in patients with et
-
2:45
an insight into clinical risk factors for progression in mpns
-
2:39
the most study: differences in disease progression amongst patients with low-risk mf
-
0:46
simplify studies: analysis of the meaningful symptomatic change in patients with myelofibrosis
-
1:34
are thrombotic risk and progression in et predictable?
-
9:25
mgus diagnosis: a step-by-step approach
-
33:24
which mpn treatment is right for you? what you need to know
-
2:28
advancements in mogad diagnosis: key features of the new guidelines
-
1:19
telomerase inhibition as a novel targeted therapy for myelofibrosis
-
1:30
recent advancements in bpdcn: diagnostic criteria, pathophysiology, and treatment
-
0:56
microbiota in hematologic malignancies
-
1:20
impact of tp53 mutations on outcomes in myelofibrosis
-
1:32
epigenetic drivers of disease progression in multiple myeloma
-
3:49
factors influencing mpn progression
-
2:20
risk factors for progression in mpns
-
4:16
pre-mds states: identifying patients at risk and using modern tools to improve prognosis
-
1:03
an insight into the sequencing of immunotherapies in adults with all
-
1:06
long-term outcomes of the ocean study: melflufen is superior to pomalidomide in r/r myeloma
-
1:13
the current bsh guidelines for the diagnosis and evaluation of prognosis of myelofibrosis
-
1:27
insights into the reveal trial: the efficacy of ruxolitinib for the treatment of patients with pv